Comparing two methods of breast reconstruction after mastectomy and radiation therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and outcomes of delayed-immediate breast reconstruction versus traditional delayed reconstruction in women undergoing mastectomy and post-mastectomy radiation therapy for breast cancer. The delayed-immediate method involves performing a skin-sparing mastectomy and immediate reconstruction with a silicone implant, aiming to preserve the native skin for better aesthetic results. Participants will be randomized to receive either reconstruction method, and outcomes such as complication rates, morbidity, aesthetic satisfaction, and psychological well-being will be assessed. The goal is to determine if the delayed-immediate approach can improve overall patient outcomes compared to the delayed reconstruction method.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Woman \>18 years who are offered a mastectomy for invasive breast can-cer pT1-3, pN0-N3, M0 and wish reconstruction. The patient can be inclu-ded no matter the status of estrogen receptor, progesterone receptor, malignancy grade, and HER2 status.
* The patient is a candidate for loco-regional radiation therapy according to national or institutional guidelines.
* Highly selected patients with inflammatory breast cancer, namely those with complete or near complete response to neoadjuvant systemic thera-py judged by imaging and clinical examination before surgery. Any skin edema and clinical signs of skin involvement must have disappeared during systemic therapy. It is highly recommended that the decision to offer an inflammatory breast cancer patient inclusion in the DBCG RT Recon trial is made during a multidisciplinary team conference.
* Adjuvant systemic therapy with chemotherapy, endocrine therapy, anti-HER2 treatment and other targeted therapies used in the adjuvant setting either as new standard or as part of a trial during the course of the trial is accepted.
* Neoadjuvant chemotherapy and primary systemic therapy of an operable breast cancer is accepted.
* Patient with previous non-breast malignancy is accepted if the patient has been without disease minimum 5 years, and the treating oncologist esti-mates a low risk of recurrence. Patients with the following diseases can be accepted despite less than 5 years disease free interval: carcinoma in situ cervicis, carcinoma in situ coli, melanoma in situ, basal cell carcino-ma of the skin, squamous cell carcinoma of the skin.
* Life expectancy minimum 10 years.

Exclusion Criteria:

* Pregnant or lactating.
* Previous breast cancer or Ductal carcinoma in Situ (DCIS).
* Bilateral breast cancer.
* Previous radiation therapy to the chest region.
* Previous non-breast malignancy (not including carcinoma in situ of the cervix or colon, melanoma in situ, basal cell carcinoma of the skin, and squamous cell carcinoma of the skin) within 5 years.
* Conditions indicating that the patient cannot go through breast reconstruction, the radiation therapy or follow up.
* Not being able to participate due to language or other personal issues.
* Life expectancy less than 10 years.

Where it's running

• Gentofte Hospital/Herlev Hospital
  Copenhagen, Denmark Recruiting
• Åbenrå Sygehus
  Aabenraa, Denmark Withdrawn
• Ålborg Universitetshospital
  Aalborg, Denmark Withdrawn
• Århus Universitets Hospital
  Aarhus, Denmark Suspended
• Esbjerg Sygehus
  Esbjerg, Denmark Withdrawn
• Sjællands Universitetshospital
  Roskilde, Denmark Not yet recruiting

Study contacts

• Principal investigator: Tove F Tvedskov, DMSc — Dbcg
• Study coordinator: Tove F Tvedskov, DMSc
• Email: tove.holst.filtenborg.tvedskov@regionh.dk
• Phone: +4535451028

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-Treatment Breast DCE-MRI AI Model to Predict Benefit from Neoadjuvant Chemo in Locally Advanced Triple-Negative Breast Cancer

  This study tests an AI model using pre-treatment breast MRI to see if it can identify which locally advanced triple-negative breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07880600

• Using Doppler ultrasound resistive index to distinguish benign and malignant breast masses

  This study will test whether comparing Doppler resistive index values from a breast mass and nearby healthy breast tissue can help tell if a solid breast lump in women is benign or malignant.

  Recruiting Karamanoğlu Mehmetbey University · Karaman, Lütfen Seçiniz. · NCT07465523

• Time‑restricted eating (8‑hour window) during chemotherapy for breast cancer: feasibility and acceptability

  This trial will test whether eating all daily food within an 8‑hour window is practical and acceptable for people starting chemotherapy for stage I–III breast cancer (and some stage IV with oncologist approval).

  Recruiting at 2 sites University of Illinois Chicago · Chicago, Illinois and 1 other locations · NCT07387445

• Implant-based breast reconstruction after bariatric (weight-loss) surgery

  This registry-based project will use national data to see how common breast implants are and whether women who've had bariatric weight-loss surgery have different complication rates after implant-based breast augmentation or reconstruction.

  Recruiting Vastra Gotaland Region · Gothenburg · NCT07059104

• Long-term follow-up of Motiva silicone breast implants

  This project sees if Motiva silicone breast implants are safe and work well over up to 10 years for adult women having primary or revision breast augmentation.

  Recruiting at 33 sites Motiva USA LLC · Beverly Hills, California and 32 other locations · NCT06938399

• FYI on MRI: decision support to help high-risk Black and Latina women decide about screening breast MRI

  This project will test whether adding a decision aid to risk assessment and nurse referral helps high-risk Black and Latina women make informed choices about screening breast MRI.

  Recruiting Georgetown University · Washington D.C., District of Columbia · NCT06892275

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.